AR021751A1 - MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS - Google Patents
MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININSInfo
- Publication number
- AR021751A1 AR021751A1 ARP990103922A ARP990103922A AR021751A1 AR 021751 A1 AR021751 A1 AR 021751A1 AR P990103922 A ARP990103922 A AR P990103922A AR P990103922 A ARP990103922 A AR P990103922A AR 021751 A1 AR021751 A1 AR 021751A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- different
- alkyloxy
- group
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos monocíclicos de la formula general (1) donde: X1, X2, X3, X4, ya sean iguales o diferentes, forman un grupo seleccionado entre: -CONR-, -NRCO-,-CH2-NR-, -NR-CH2- donde R es H, alquilo C1-3, bencilo; f y m, ya sean iguales o diferentes, sonun numero seleccionado entre 0, 1 y 2; R1 y R2, ya seaniguales o diferentes, forman un grupo -(CH2)r-Ar, donde r es igual a 0, 1, 2 y Ar es un grupo aromático seleccionado entre: benceno, naftalina, tiofeno,benzotiofeno, piridina, quinolina, indol,furano, benzofuran, tiazol, benzotiazol, imidazol, benzoimidazol, con posibilidad de sustitucion por medio de hasta 2sustitutos seleccionados entre alquilo C1-3, haloalquilo, alquiloxi C1-3, amino C2-4-alquiloxi, halogenos, OH, NH2, CN, NR6R7, dondeR6 y R7, ya sean iguales odiferentes, son H o alquilo C1-3; R3 es un grupo seleccionado entre los siguientes grupos: -(CH2)r-Ar1 donde r es igual a 0, 1, 2 y Ar1 es un grupo aromáticoseleccionado entre: benceno, naftalina, tiofeno, benzotiofeno, piridina, quinolina, indol, furano, benzofurano, tiazol, benzotiazol, imidazol, benzoimidazol,con posibilidad de sustitucion por medio de hasta 2 sustitutos seleccionados entre alquilo C1-3 y haloalquilo, alquiloxi C1-3 y amino alquiloxi, halogenos, OH,NH2, CN, NR6R7, donde R6 y R7, ya sean iguales o diferentes, son H o alquilo C1-3; R5 es H; R4 es un grupo seleccionado entre: -NR8R9, donde R8 es H o alquiloC1-3 y R9 es un metanosulfonilo, tosilo, tetrahidropiranilo, tetrahidrotiopiranilo, posiblemente mono o bisustituido por oxígeno en el átomo S, piperidiloposiblemente sustituido en el átomo N por un alquilo C1-3, acilo C1-3, amino sulfonilo, metanosulfonilo; o un grupo (CH2)g-R10 donde g es 1, 2, 3 y R10 seselecciona entre morfolino, furano,CN; o R8 y R9 junto con el átomo N al que están vinculados forman piperacina posiblemente sustituida en uno de susnitrogenos por alquilo C1-3, acilo C1-3 o metanosulfonilo; N(R11)CO(CH2)h-R12 donde R11 es H o alquilo C1-3; h es 0, 1, 2, 3; y R12 seselecciona entre:morfolino, pirrolidino posiblemente sustituido por hidroxi o hidroximetil, piperidina posiblemente sustituido por un grupo hidroxicarboxilamido oMonocyclic compounds of the general formula (1) where: X1, X2, X3, X4, whether the same or different, form a group selected from: -CONR-, -NRCO -, - CH2-NR-, -NR-CH2- where R is H, C1-3 alkyl, benzyl; f and m, whether the same or different, are a number selected from 0, 1 and 2; R1 and R2, whether equal or different, form a group - (CH2) r-Ar, where r is equal to 0, 1, 2 and Ar is an aromatic group selected from: benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline , indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, with the possibility of substitution by means of up to 2 substitutes selected from C1-3 alkyl, haloalkyl, C1-3 alkyloxy, C2-4-alkyloxy, halogens, OH, NH2 , CN, NR6R7, where R6 and R7, whether equal or different, are H or C1-3 alkyl; R3 is a group selected from the following groups: - (CH2) r-Ar1 where r is equal to 0, 1, 2 and Ar1 is an aromatic group selected from: benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan , benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, with the possibility of substitution by means of up to 2 substitutes selected from C1-3 alkyl and haloalkyl, C1-3 alkyloxy and amino alkyloxy, halogens, OH, NH2, CN, NR6R7, where R6 and R7, whether the same or different, are H or C1-3 alkyl; R5 is H; R4 is a group selected from: -NR8R9, where R8 is H or C1-3alkyl and R9 is a methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl, possibly mono or bis-substituted by oxygen in the S atom, piperidylpossibly substituted on the N atom by an alkyl C1-3, C1-3 acyl, amino sulfonyl, methanesulfonyl; or a group (CH2) g-R10 where g is 1, 2, 3 and R10 is selected from morpholino, furan, CN; or R8 and R9 together with the N atom to which they are linked form piperazine possibly substituted in one of susnitrogens by C1-3 alkyl, C1-3 acyl or methanesulfonyl; N (R11) CO (CH2) h-R12 where R11 is H or C1-3 alkyl; h is 0, 1, 2, 3; and R12 is selected from: morpholino, pyrrolidino possibly substituted by hydroxy or hydroxymethyl, piperidine possibly substituted by a hydroxycarboxylamide group or
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1998FI000186A IT1304888B1 (en) | 1998-08-05 | 1998-08-05 | MONOCYCLIC ACTION COMPOUNDS NK-2 ANTAGONIST AND FORMULATIONS THAT CONTAIN |
Publications (1)
Publication Number | Publication Date |
---|---|
AR021751A1 true AR021751A1 (en) | 2002-08-07 |
Family
ID=11352646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990103922A AR021751A1 (en) | 1998-08-05 | 1999-08-05 | MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1102789A1 (en) |
JP (1) | JP2002522450A (en) |
AR (1) | AR021751A1 (en) |
AU (1) | AU5507999A (en) |
CA (1) | CA2339638A1 (en) |
CO (1) | CO5080789A1 (en) |
IT (1) | IT1304888B1 (en) |
PE (1) | PE20001002A1 (en) |
TR (1) | TR200100354T2 (en) |
TW (1) | TW491857B (en) |
WO (1) | WO2000008046A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1307809B1 (en) * | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | BASIC MONOCYCLIC COMPOUNDS WITH NK-2 ANTAGONIST ACTION, MANUFACTURING PROCESSES AND FORMULATIONS CONTAINING THEM. |
PL217630B1 (en) | 2003-04-24 | 2014-08-29 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
UY38485A (en) | 2018-11-27 | 2020-06-30 | Novartis Ag | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703034A (en) * | 1986-04-28 | 1987-10-27 | Merck & Co., Inc. | Novel cyclic tetrapeptide |
AU2387592A (en) * | 1991-08-08 | 1993-03-02 | A. Menarini Industrie Farmaceutiche Riunite S.R.L. | Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof |
ATE155486T1 (en) * | 1991-08-13 | 1997-08-15 | Takeda Chemical Industries Ltd | CYCLIC PEPTIDES AND THEIR USE |
IT1277835B1 (en) * | 1995-03-13 | 1997-11-12 | Menarini Farma Ind | BICYCLE COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS |
IT1291776B1 (en) * | 1997-02-07 | 1999-01-21 | Menarini Ricerche Spa | MONOCYCLIC COMPOUNDS WITH FOUR BIFUNCTIONAL RESIDUES, HAVING NK-2 ANTAGONIST ACTION |
-
1998
- 1998-08-05 IT IT1998FI000186A patent/IT1304888B1/en active
-
1999
- 1999-07-27 TW TW088112671A patent/TW491857B/en active
- 1999-07-30 CA CA002339638A patent/CA2339638A1/en not_active Abandoned
- 1999-07-30 TR TR2001/00354T patent/TR200100354T2/en unknown
- 1999-07-30 WO PCT/EP1999/005459 patent/WO2000008046A1/en not_active Application Discontinuation
- 1999-07-30 AU AU55079/99A patent/AU5507999A/en not_active Abandoned
- 1999-07-30 EP EP99941479A patent/EP1102789A1/en not_active Withdrawn
- 1999-07-30 JP JP2000563679A patent/JP2002522450A/en active Pending
- 1999-08-04 PE PE1999000784A patent/PE20001002A1/en not_active Application Discontinuation
- 1999-08-05 AR ARP990103922A patent/AR021751A1/en unknown
- 1999-08-05 CO CO99049466A patent/CO5080789A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002522450A (en) | 2002-07-23 |
WO2000008046A1 (en) | 2000-02-17 |
CO5080789A1 (en) | 2001-09-25 |
AU5507999A (en) | 2000-02-28 |
IT1304888B1 (en) | 2001-04-05 |
CA2339638A1 (en) | 2000-02-17 |
EP1102789A1 (en) | 2001-05-30 |
PE20001002A1 (en) | 2000-10-16 |
TW491857B (en) | 2002-06-21 |
TR200100354T2 (en) | 2001-05-21 |
ITFI980186A1 (en) | 2000-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2203272C2 (en) | Substituted bicyclic compounds, parent and intermediate substances for their synthesis and pharmaceutical composition based on thereof | |
UY27322A1 (en) | NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER | |
AR055878A1 (en) | CYCLOPROPANOCARBOXAMIDE DERIVATIVES | |
ES2185665T3 (en) | DERIVATIVES OF BENZOFURAN AS AN TAGYCIN ANTAGONISTS. | |
ES2082013T3 (en) | MUSCARINIC RECEPTOR ANTAGONISTS. | |
ES2150918T3 (en) | 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINAS 1-SUBSTITUTED; INTERMEDIATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS. | |
PE20030431A1 (en) | QUINUCLIDINE DERIVATIVES AS AGONISTS OF THE NICOTINE RECEPTOR OF ACETYLCHOLINE TYPE a7 | |
EA200970704A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTAGONISTS OF NK1 RECEPTOR AND NA CHANNEL BLOCKERS | |
UY27336A1 (en) | 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | |
ES2157593T3 (en) | DERIVED FROM THE HETEROCICLIC ADENOSINE REPLACED IN N6. | |
ES2064310T3 (en) | PROCEDURE FOR PREPARING IMIDAZOPYRIDINE COMPOUNDS. | |
PE20030257A1 (en) | 8-AZA-11-DEOXY-PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | |
IS2503B (en) | New compounds | |
PE20060457A1 (en) | DIPHENYL ETHER DERIVATIVES AS ANTAGONISTS OF 5HT2 RECEPTORS | |
MX2009007914A (en) | Novel pharmaceutical compositions. | |
YU53100A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists | |
ES2059873T3 (en) | 2-ALKYNYLPHENOLS SUBSTITUTED WITH ANTI-INFLAMMATORY ACTIVITY, A PROCEDURE FOR ITS PREPARATION AND ITS PHARMACEUTICAL COMPOSITIONS. | |
UY24429A1 (en) | ACETIDINS | |
AR021751A1 (en) | MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS | |
ES2045126T3 (en) | THERAPEUTIC AGENTS. | |
AR006189A1 (en) | AMINOALKYL-ETERS AND ACILAMINOALKYL-ETERES, PROCEDURE FOR THEIR PREPARATION AND USE AS BRADIQUININE RECEPTOR ANTAGONISTS | |
AR016198A1 (en) | A COMPOUND THAT IS A DISTAMICIN DERIVATIVE REPLACED WITH ACRYLILE, ITS USE, A PROCEDURE TO PREPARE IT AND A PHARMACEUTICAL COMPOSITION THAT LOCOMPRESSES | |
PE20030611A1 (en) | LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS | |
AR065208A1 (en) | DERIVATIVES OF TETRAHYDRONAFTALENE SUBSTITUTED WITH HETEROCICLES OR ITS BENEFITED ANALOGS, METHOD OF PREPARATION, MEDICINES CONTAINING THEMSELVES AND USES OF THE SAME, AS LEGENDS OF RECEPTORS 5-HT7, IN PATHOLOGIES ASSOCIATED WITH SNC. | |
ES2187783T3 (en) | INDOLINE DERIVATIVES USEFUL AS ANTAGONISTS OF THE 5-HT-2C RECEIVER. |